PTC Therapeutics completes acquisition of Sangamo’s ST-920 Fabry gene therapy asset
Bitget2026/09/21 20:30- PTC Therapeutics completed its acquisition of Sangamo’s ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease.
- A rolling BLA filing to the FDA for accelerated approval is expected to be completed in Q4 2026.
- ST-920, also known as isaralgagene civaparvovec, targets long-term α-Gal A enzyme production to reduce Gb3 levels and cut reliance on ERT.
- The program holds FDA Orphan Drug, Fast Track, and RMAT designations, with similar designations in Europe and the UK.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitmine Buys 9,587 ETH as Holdings Near 5% of Ethereum Supply
Ekopak Expands Wastewater Treatment Plant at Mark Anthony Brewing
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
Crypto prices
More
